Patents Examined by Roy Teller
  • Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
    Patent number: 8211999
    Abstract: The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor immune responses. In particular, the present invention relates to 49 novel peptide sequences derived from HLA class II molecules of human tumor cell lines which can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Grant
    Filed: November 19, 2007
    Date of Patent: July 3, 2012
    Assignee: Immatics Biotechnologies GmbH
    Inventor: Jörn Dengjel
  • Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
    Patent number: 8212000
    Abstract: The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor immune responses. In particular, the present invention relates to 49 novel peptide sequences derived from HLA class II molecules of human tumor cell lines which can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Grant
    Filed: November 19, 2007
    Date of Patent: July 3, 2012
    Assignee: Immatics Biotechnologies GmbH
    Inventor: Jörn Dengjel
  • Pharmaceutical compositions for sustained release delivery of peptides
    Patent number: 8206735
    Abstract: The present invention provides methods of forming a solid, biodegradable implant in-situ in a body by administering a liquid pharmaceutical composition comprising an effective amount of a biocompatible, water-insoluble, biodegradable polymer and an effective amount of a therapeutic peptide covalently modified with one or more lipophilic or amphiphilic moieties, which are dissolved or dispersed in a biocompatible, water-soluble organic solvent. This invention also provides related compositions and methods.
    Type: Grant
    Filed: July 11, 2007
    Date of Patent: June 26, 2012
    Assignee: Foresee Pharmaceuticals, LLC
    Inventors: Yuhua Li, Benjamin Chien
  • Peptides that down regulate the activity of plasma membrane transporters including sodium-D-glucose cotransporter SGLT1
    Patent number: 8207133
    Abstract: The present invention relates to the use of a regulatory protein RS1 fragment or a nucleic acid molecule encoding said regulatory protein RS1 fragment for the preparation of a pharmaceutical composition for the amelioration, prevention and/or treatment of a metabolic disease or a secondary disorder caused by a (pathological) modification of homeostasis, wherein said RS1 fragment is characterized in comprising at least 3 consecutive amino acid residues as comprised in the amino acid sequence S-D-S-D-R-I-E-P (Serine-Aspartic acid-Serine-Aspartic acid-Arginine-Isoleucine-Glutamic acid-Proline) (SEQ ID NO: 9) or derivatives thereof.
    Type: Grant
    Filed: March 31, 2006
    Date of Patent: June 26, 2012
    Assignee: Julius-Maximilians-Universitat Wurzburg
    Inventors: Herman Koepsell, Alexandra Vernaleken
  • Fat regulation
    Patent number: 8202834
    Abstract: The present invention provides methods and compounds for regulating fat metabolism and achieving fat homeostasis in a subject. Methods and compound for regulating body weight, reducing body fat, and inducing weight loss are also provided, as are methods and compounds for treating or preventing obesity and for preventing or treating conditions associated with altered fat metabolism including, e.g., obesity, diabetes, atherosclerosis, etc.
    Type: Grant
    Filed: October 19, 2009
    Date of Patent: June 19, 2012
    Assignee: FibroGen, Inc.
    Inventors: Patrick D. Fourney, Volkmar Guenzler-Pukall, Stephen J. Klaus, Al Y. Lin, Thomas B. Neff, Todd W. Seeley
  • Therapeutic and cosmetic compositions for treatment of skin
    Patent number: 8188047
    Abstract: The present invention is directed to a skin cream containing L-glutathione and methyl sulfone in combination with perfluorodecalin and various vitamins such as Vitamin D and C. The cream can be used to treat cancerous and precancerous diseases found in or on the skin.
    Type: Grant
    Filed: March 20, 2009
    Date of Patent: May 29, 2012
    Inventor: Thomas Perez
  • Reconstituted surfactants having improved properties
    Patent number: 8183210
    Abstract: Reconstituted surfactants comprising a lipid carrier, a polypeptide analog of the native surfactant protein SP-C, and a polypeptide analog of the native surfactant protein SP-B are useful for the treatment and/or prophylaxis of RDS and other respiratory disorders.
    Type: Grant
    Filed: April 13, 2009
    Date of Patent: May 22, 2012
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Jan Johansson, Tore Curstedt, Bengt Robertson, Joakim Robertson, legal representative, Soeren Robertson, legal representative, Magnus Robertson, legal representative, Charlotte Robertson, legal representative, Gertie Robertson Grossmann, legal representative
  • Methods and compositions for increasing skin remodeling
    Patent number: 8183204
    Abstract: Skin remodeling is stimulated at the site of blemished skin using an ionic metal-peptide complex to diminish or remove the skin imperfection. The blemish can be a scar, especially surgical or wound scars, acne scars, keloid scars, and the like, or a skin tag, callus, benign skin mole, stretch marks, facial keratosis, thickened sunspots of the skin, or a vitiligo spot. The peptide-ionic metal complex is comprised of an ionic metal selected from copper(II), tin(II), tin(IV), and zinc(II), and salts thereof, and the peptide component can be a hydrolysis of casein, collagen, elastin, meat products, silk protein, or soybean protein, or a chemically synthesized dipeptide, tripeptide, tetrapeptide or the like which complexes with the ionic metal.
    Type: Grant
    Filed: July 8, 2008
    Date of Patent: May 22, 2012
    Assignee: Summit Associates International Inc.
    Inventor: Loren R. Pickart
  • Methods and compositions for the inhibition of thrombus formation
    Patent number: 8173595
    Abstract: The present invention is directed to anti-platelet peptides that may be used in various methods for the treatment or prophylaxis of thrombosis. More specifically, the specification describes methods and compositions for making and using compositions GPIb? fragments as anti-platelet agents. The present invention is also directed to peptides that inhibit intracellular function of 14-3-3.
    Type: Grant
    Filed: April 27, 2005
    Date of Patent: May 8, 2012
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Kesheng Dai, Xiaoping Du
  • Methods of making and using surfactant polymers
    Patent number: 8163302
    Abstract: Comblike, surfactant polymers for changing the surface properties of biomaterials are provided. Such surfactant polymers comprise a polymeric backbone of repeating monomeric units having functional groups for coupling with side chains, a plurality of hydrophobic side chains linked to the backbone via the functional groups, and a plurality of hydrophilic side chains linked to said backbone via the functional groups. Medical devices coated with the surfactant polymers are also provided. The surfactant polymers may be used to decrease the thrombogenic properties, encapsulation, and bacterial colonization of medical devices.
    Type: Grant
    Filed: April 4, 2008
    Date of Patent: April 24, 2012
    Assignee: NanoMimetics, Inc.
    Inventors: Roger E. Marchant, Tianhong Zhang, Yongxing Qiu, Mark A. Ruegsegger
  • Process for producing an injectable medicament preparation
    Patent number: 8153581
    Abstract: The invention relates to a method for producing injectable medicament preparations containing a therapeutically and/or diagnostically effective substance which is comprised of an active agent, of a spacer molecule and of at least one protein-binding molecule. After being brought into contact with the body, said therapeutically and/or diagnostically effective substance covalently bonds to the body fluid constituents or tissue constituents via the protein-binding molecule, thus providing a form of transport of the active agent that an be hydrolytically or enzymatically cleaved, according to pH, in the body while releasing the active agent.
    Type: Grant
    Filed: October 22, 2009
    Date of Patent: April 10, 2012
    Assignee: KTB Tumorforschungs GmbH
    Inventor: Felix Kratz
  • Peptidic vasopressin receptor agonists
    Patent number: 8148319
    Abstract: The present invention relates to novel compounds, pharmaceutical compositions comprising the same, use of said compounds for the manufacture of a medicament for treatment of inter alia shock conditions as well as to a method for treatment of said conditions, wherein said compounds are administered. The compounds are represented by the general formula (I), as further defined in the specification.
    Type: Grant
    Filed: August 3, 2005
    Date of Patent: April 3, 2012
    Assignee: Ferring B.V.
    Inventors: Kazimierz Wisniewski, Claudio Schteingart, Regent Laporte, Robert Felix Galyean, Pierre Riviere
  • Bioactive peptides
    Patent number: 8143211
    Abstract: The present invention provides a cytotoxic 7 to 25-mer peptide with three or more cationic residues which has one or more non-generic bulky and lipophilic amino acids, as well as esters, amides, salts and cyclic derivatives thereof as well as methods of preparing the peptides, pharmaceutical compositions containing them, and their use as medicaments, particularly as antibacterial or antitumor agents.
    Type: Grant
    Filed: July 2, 2008
    Date of Patent: March 27, 2012
    Assignee: Lytix Biopharma AS
    Inventors: John Sigurd Svendsen, Øystein Rekdal, Baldur Sveinbjørnsson, Lars Vorland
  • CLK-peptide and SLK-peptide
    Patent number: 8133471
    Abstract: The invention describes methods for inhibiting angiogenesis in a tissue by administering an antagonist that specifically binds to a proteolyzed or denatured collagen type-IV with substantially greater affinity than to the native triple helical form of collagen type-IV. Methods utilizing such antagonists for therapeutic treatment of tumor growth, tumor metastasis or of restenosis also are described, as are methods to use such antagonists as diagnostic markers of angiogenesis in normal or diseased tissues both in vivo and ex vivo. The invention further describes methods for treating tumors using said antagonists in combination with radiation therapy and therapies comprising the antagonists and radiation treatment.
    Type: Grant
    Filed: December 21, 2009
    Date of Patent: March 13, 2012
    Assignee: New York University
    Inventors: Peter C. Brooks, Jennifer Roth, Abebe Akalu
  • Bardet-Biedl susceptibility gene and uses thereof
    Patent number: 8129161
    Abstract: The present invention relates to the identification of a gene, now designated negevin (ngvn), that is involved in the genetic disease Bardet Biedl Syndrome (BBS), which is characterized by such diverse symptoms as obesity, diabetes, hypertension, mental retardation, renal cancer and other abnormalities, retinopathy and hypogonadism. The human NGVN protein disclosed herein is 731 amino acids in length and is coded for by a gene spanning 17 exons. Homologs have been identified in mouse, rat, zebrafish. Methods of use for the gene, for example in diagnosis and therapy of BBS and in drug screening, also are described.
    Type: Grant
    Filed: October 20, 2010
    Date of Patent: March 6, 2012
    Assignee: The University of Iowa Research Foundation
    Inventors: Val Sheffield, Darryl Nishimura, Edwin Stone
  • Processes for intermediates for macrocyclic compounds
    Patent number: 8129561
    Abstract: The present invention is directed to novel macrocyclic compounds of formula (I) and their pharmaceutically acceptable salts, hydrates or solvates: wherein R1, R2, R3, R4, R5, R6, n1, m, p Z1, Z2, and Z3 are as describe in the specification. The invention also relates to compounds of formula (I) which are antagonists of the motilin receptor and are useful in the treatment of disorders associated with this receptor and with or with motility dysfunction.
    Type: Grant
    Filed: November 19, 2008
    Date of Patent: March 6, 2012
    Assignee: Tranzyme Pharma Inc.
    Inventors: Eric Marsault, Luc Ouellet, Hamid R. Hoveyda
  • Compositions comprising epigallocatechin gallate and protein hydrolysate
    Patent number: 8129337
    Abstract: The present invention describes a composition comprising EGCG and a protein hydrolysate.
    Type: Grant
    Filed: February 2, 2006
    Date of Patent: March 6, 2012
    Assignee: DSM IP Assets B.V.
    Inventor: Swen Wolfram
  • Stabilized preparations of serine endopeptidases, their preparation and use
    Patent number: 8124737
    Abstract: The invention relates to stabilized preparations of serine endopeptidases which are suitable for use as a test reagent in a diagnostic procedure or for a therapeutic use. As a result of the addition of various additives, the preparations have improved stability and shelf life.
    Type: Grant
    Filed: February 23, 2007
    Date of Patent: February 28, 2012
    Assignee: Seimens Healthcare Diagnostics Products GmbH
    Inventors: Andrea Lichte, Verena Kräling
  • Treatment of diabetes
    Patent number: 8124582
    Abstract: The present invention relates to methods and compounds for regulating glucose metabolism, achieving glucose homeostasis, and decreasing blood glucose levels. Methods and compounds for treating or preventing diabetes, hyperglycemia, and disorders and conditions associated with altered or impaired glucose metabolism are also provided.
    Type: Grant
    Filed: December 4, 2003
    Date of Patent: February 28, 2012
    Assignee: FibroGen, Inc.
    Inventors: Volkmar Guenzler-Pukall, Stephen J. Klaus, Ingrid Langsetmo Parobok, Todd W. Seeley
  • Use of selected cyclosporins for the treatment of hepatitis C infection
    Patent number: RE43371
    Abstract: This invention relates to the use in the treatment of HCV infection, either as single active agents or in combination with another active agent, of a cyclosporin having increased cyclophilin binding activity and essentially lacking immunosuppressive activity.
    Type: Grant
    Filed: October 29, 2010
    Date of Patent: May 8, 2012
    Inventors: Pietro Scalfaro, Jean-Maurice Dumont, Gregoire Vuagniaux, Rolland-Yves Mauvernay